In a study SCT appeared linked to an increased risk of pregnancy-associated VTE, pulmonary embolism, and isolated DVT.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
Clinicians have an important role in helping donation centers make the most of exciting advances and meet recent challenges.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Approval was based on data from the AGAVE-201 trial and is for use in adult and pediatric patients who weigh at least 40 kg.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Patients receiving mitapivat showed a statistically significant hemoglobin response rate compared with placebo.
Study data show the VAS-101 gel formulation helps preserve therapeutic efficacy and extend useful longevity of stored RBCs.
The tranexamic acid and placebo groups did not differ in occurrence of thrombotic events or veno-occlusive disease.
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Questions surrounding informed consent, mandatory versus optional biopsy, and safety for adults and children are addressed.
In a phase 1 trial presented at ASH 2024, clinical benefit was observed in 100% of patients receiving LYT-200 monotherapy.
Advertisement
Conference Coverage
Major highlights with a focus on MDS from the 66th American Society of Hematology Annual Meeting & Exposition
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Expert Interviews on Hematology
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.